Mavers Lab

Work in our lab focuses on immune regulation in hematopoietic stem cell transplantation (HSCT) and on developing novel platforms for cellular therapies. HSCT can cure high-risk malignancies and other diseases of the blood and bone marrow, yet success is limited as many patients develop graft-versus-host disease (GVHD), a debilitating and potentially fatal complication of HSCT.

We aim to elucidate the biological mechanisms underlying immune tolerance in HSCT, develop approaches to enhance regulatory immune cells for GVHD prevention and design improved cancer targeting cellular therapies for safer and more effective treatment. Our goal is to use a bench-to-bedside approach to engineer viable cell-based therapeutics for preventative and curative treatments, thereby making HSCT and cellular therapies safer ways to cure cancer and other blood diseases, giving survivors long, healthy lives.

Work in the Mavers lab has received support from:

Hyundai Hope on Wheels

Cancer Research Foundation

National Institutes of Health (NHLBI)

Pedal The Cause

Siteman Cancer Center

News

Arnav and Joanne present at the Fall 2024 Undergraduate Research Symposium

November 1, 2024

Arnav presented a poster on his work from the Summer Public Health Scholars program on public health literacy and Joanne presented a poster on her work on iNKT cell activation.

Emily presents her work at the Siteman Catalyst Awards Reception

October 17, 2024

Emily and Melissa met the donors who made the single cell RNA sequencing project possible and enjoyed an evening of new connections and engaging conversations.

Mavers receives the Hyundai Hope on Wheels Hope Scholar Award

September 25, 2024

Melissa Mavers, MD, PhD, receives the Hyundai Hope on Wheels Hope Scholar Award to further support our work on graft-versus-host-disease!

Follow us

• mmaversmdphd